FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115046089> ?p ?o ?g. }

• W2115046089 endingPage "538" @default.
• W2115046089 startingPage "527" @default.
• W2115046089 abstract "The phe508del CFTR mutation causes cystic fibrosis by limiting the amount of CFTR protein that reaches the epithelial cell surface. We tested combination treatment with lumacaftor, an investigational CFTR corrector that increases trafficking of phe508del CFTR to the cell surface, and ivacaftor, a CFTR potentiator that enhances chloride transport of CFTR on the cell surface.In this phase 2 clinical trial, we assessed three successive cohorts, with the results of each cohort informing dose selection for the subsequent cohort. We recruited patients from 24 cystic fibrosis centres in Australia, Belgium, Germany, New Zealand, and the USA. Eligibility criteria were: confirmed diagnosis of cystic fibrosis, age at least 18 years, and a forced expiratory volume in 1 s (FEV1) of 40% or more than predicted. Cohort 1 included phe508del CFTR homozygous patients randomly assigned to either lumacaftor 200 mg once per day for 14 days followed by addition of ivacaftor 150 mg or 250 mg every 12 h for 7 days, or 21 days of placebo. Together, cohorts 2 and 3 included phe508del CFTR homozygous and heterozygous patients, randomly assigned to either 56 days of lumacaftor (cohort 2: 200 mg, 400 mg, or 600 mg once per day, cohort 3: 400 mg every 12 h) with ivacaftor 250 mg every 12 h added after 28 days, or 56 days of placebo. The primary outcomes for all cohorts were change in sweat chloride concentration during the combination treatment period in the intention-to-treat population and safety (laboratory measurements and adverse events). The study is registered with ClinicalTrials.gov, number NCT01225211, and EudraCT, number 2010-020413-90.Cohort 1 included 64 participants. Cohort 2 and 3 combined contained 96 phe508del CFTR homozygous patients and 28 compound heterozygotes. Treatment with lumacaftor 200 mg once daily and ivacaftor 250 mg every 12 h decreased mean sweat chloride concentration by 9.1 mmol/L (p<0.001) during the combination treatment period in cohort 1. In cohorts 2 and 3, mean sweat chloride concentration did not decrease significantly during combination treatment in any group. Frequency and nature of adverse events were much the same in the treatment and placebo groups during the combination treatment period; the most commonly reported events were respiratory. 12 of 97 participants had chest tightness or dyspnoea during treatment with lumacaftor alone. In pre-planned secondary analyses, a significant decrease in sweat chloride concentration occurred in the treatment groups between day 1 and day 56 (lumacaftor 400 mg once per day group -9.1 mmol/L, p<0.001; lumacaftor 600 mg once per day group -8.9 mmol/L, p<0.001; lumacaftor 400 mg every 12 h group -10.3 mmol/L, p=0.002). These changes were significantly greater than the change in the placebo group. In cohort 2, the lumacaftor 600 mg once per day significantly improved FEV1 from day 1 to 56 (difference compared with placebo group: +5.6 percentage points, p=0.013), primarily during the combination period. In cohort 3, FEV1 did not change significantly across the entire study period compared with placebo (difference +4.2 percentage points, p=0.132), but did during the combination period (difference +7.7 percentage points, p=0·003). Phe508del CFTR heterozygous patients did not have a significant improvement in FEV1.We provide evidence that combination lumacaftor and ivacaftor improves FEV1 for patients with cystic fibrosis who are homozygous for phe508del CFTR, with a modest effect on sweat chloride concentration. These results support the further exploration of combination lumacaftor and ivacaftor as a treatment in this setting.Vertex Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics Development Network." @default.
• W2115046089 created "2016-06-24" @default.
• W2115046089 creator A5000385368 @default.
• W2115046089 creator A5003155363 @default.
• W2115046089 creator A5010965110 @default.
• W2115046089 creator A5020072100 @default.
• W2115046089 creator A5021191544 @default.
• W2115046089 creator A5041794497 @default.
• W2115046089 creator A5071091256 @default.
• W2115046089 creator A5080088656 @default.
• W2115046089 creator A5080398176 @default.
• W2115046089 creator A5081431279 @default.
• W2115046089 date "2014-07-01" @default.
• W2115046089 modified "2023-09-30" @default.
• W2115046089 title "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial" @default.
• W2115046089 cites W1995458929 @default.
• W2115046089 cites W2016728833 @default.
• W2115046089 cites W2022634662 @default.
• W2115046089 cites W2026654573 @default.
• W2115046089 cites W2031502609 @default.
• W2115046089 cites W2035131077 @default.
• W2115046089 cites W2058814112 @default.
• W2115046089 cites W2071407356 @default.
• W2115046089 cites W2090648579 @default.
• W2115046089 cites W2099049651 @default.
• W2115046089 cites W2103043501 @default.
• W2115046089 cites W2116707205 @default.
• W2115046089 cites W2131236190 @default.
• W2115046089 cites W2132775040 @default.
• W2115046089 cites W2140868856 @default.
• W2115046089 cites W2151837778 @default.
• W2115046089 cites W2170032136 @default.
• W2115046089 cites W2333398204 @default.
• W2115046089 cites W4241884576 @default.
• W2115046089 doi "https://doi.org/10.1016/s2213-2600(14)70132-8" @default.
• W2115046089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24973281" @default.
• W2115046089 hasPublicationYear "2014" @default.
• W2115046089 type Work @default.
• W2115046089 sameAs 2115046089 @default.
• W2115046089 citedByCount "367" @default.
• W2115046089 countsByYear W21150460892014 @default.
• W2115046089 countsByYear W21150460892015 @default.
• W2115046089 countsByYear W21150460892016 @default.
• W2115046089 countsByYear W21150460892017 @default.
• W2115046089 countsByYear W21150460892018 @default.
• W2115046089 countsByYear W21150460892019 @default.
• W2115046089 countsByYear W21150460892020 @default.
• W2115046089 countsByYear W21150460892021 @default.
• W2115046089 countsByYear W21150460892022 @default.
• W2115046089 countsByYear W21150460892023 @default.
• W2115046089 crossrefType "journal-article" @default.
• W2115046089 hasAuthorship W2115046089A5000385368 @default.
• W2115046089 hasAuthorship W2115046089A5003155363 @default.
• W2115046089 hasAuthorship W2115046089A5010965110 @default.
• W2115046089 hasAuthorship W2115046089A5020072100 @default.
• W2115046089 hasAuthorship W2115046089A5021191544 @default.
• W2115046089 hasAuthorship W2115046089A5041794497 @default.
• W2115046089 hasAuthorship W2115046089A5071091256 @default.
• W2115046089 hasAuthorship W2115046089A5080088656 @default.
• W2115046089 hasAuthorship W2115046089A5080398176 @default.
• W2115046089 hasAuthorship W2115046089A5081431279 @default.
• W2115046089 hasConcept C126322002 @default.
• W2115046089 hasConcept C141071460 @default.
• W2115046089 hasConcept C142724271 @default.
• W2115046089 hasConcept C197934379 @default.
• W2115046089 hasConcept C204787440 @default.
• W2115046089 hasConcept C27081682 @default.
• W2115046089 hasConcept C2776502428 @default.
• W2115046089 hasConcept C2776938444 @default.
• W2115046089 hasConcept C2778428886 @default.
• W2115046089 hasConcept C2908647359 @default.
• W2115046089 hasConcept C71924100 @default.
• W2115046089 hasConcept C72563966 @default.
• W2115046089 hasConcept C90924648 @default.
• W2115046089 hasConcept C99454951 @default.
• W2115046089 hasConceptScore W2115046089C126322002 @default.
• W2115046089 hasConceptScore W2115046089C141071460 @default.
• W2115046089 hasConceptScore W2115046089C142724271 @default.
• W2115046089 hasConceptScore W2115046089C197934379 @default.
• W2115046089 hasConceptScore W2115046089C204787440 @default.
• W2115046089 hasConceptScore W2115046089C27081682 @default.
• W2115046089 hasConceptScore W2115046089C2776502428 @default.
• W2115046089 hasConceptScore W2115046089C2776938444 @default.
• W2115046089 hasConceptScore W2115046089C2778428886 @default.
• W2115046089 hasConceptScore W2115046089C2908647359 @default.
• W2115046089 hasConceptScore W2115046089C71924100 @default.
• W2115046089 hasConceptScore W2115046089C72563966 @default.
• W2115046089 hasConceptScore W2115046089C90924648 @default.
• W2115046089 hasConceptScore W2115046089C99454951 @default.
• W2115046089 hasIssue "7" @default.
• W2115046089 hasLocation W21150460891 @default.
• W2115046089 hasLocation W21150460892 @default.
• W2115046089 hasOpenAccess W2115046089 @default.
• W2115046089 hasPrimaryLocation W21150460891 @default.
• W2115046089 hasRelatedWork W2128229997 @default.
• W2115046089 hasRelatedWork W2596109810 @default.
• W2115046089 hasRelatedWork W2897997652 @default.
• W2115046089 hasRelatedWork W3016750854 @default.

• next